



TOGETHER, WE DARE

Advisory and consultancy firm The Biotech Quality Group opens a French subsidiary

Firmly established in Belgium and Switzerland, BQG will consolidate its position in all French-speaking regions of Europe with its new subsidiary in France

Brussels, Belgium, July 4, 2017 – The Biotech Quality Group (BQG), an advisory firm specialized in improving the performance of biopharmaceutical and medical device companies, today announces the establishment of a subsidiary in France, with offices in Paris. Following the creation of the company in Brussels in 2011 and the establishment of its Swiss subsidiary in 2014, The Biotech Quality Group seeks to strengthen its position in all French-speaking regions of Europe.

As a pioneer in its field, BQG develops innovative methodologies and sets of services (Atlas and Apollo Maturity™) that combine both performance and regulatory compliance. The team supports several companies throughout the entire life cycle of their drug or medical device.

Ismaël Riazul, international business development director since May 2016, now takes on the role of general manager for the French subsidiary. Mr Riazul graduated as an engineer in industrial biology from the University of Cergy Pontoise (France) in 2004. Over the last 12 years, he has held various management and commercial department roles in consulting for the pharmaceutical industry in both France and Belgium. The French subsidiary of BQG today has 15 employees, including a dedicated team for clients in the Rhône-Alpes region. The company plans to hire 40 employees in France over the next three years.

“We are happy to be launching our French subsidiary. We will be able to help our clients with the various challenges associated with manufacturing high-quality products at the best price,” said Mr Riazul. “We already have several existing customers in France in the context of performance-improvement projects and we recently won a significant tender thanks to our innovative tools.”

Fabrice Dekoninck, CEO and co-founder of BQG, said: “The French pharmaceutical industry is very specific. BQG’s expansion into France will enable us to accelerate the development of our Apollo and Atlas services in the specific fields of quality integration and interconnection with their partners and within laboratories themselves. We are also very excited about the idea of being able to transfer part of our R&D, benefiting from the first-class university and academic network.”



TOGETHER, WE DARE

About the Apollo Maturity Program™ and ATLAS services

Apollo Maturity™ provides tools and a comparative diagnostic methodology to evaluate the maturity of clients' key life cycle product processes, enabling them to develop strategies and tactics to gain compliance and improve the performance of their processes. Awarded the 'Rise – Innovative Starters 2014' prize in Belgium, Apollo Maturity™ includes a suite of modules (intelligence, diagnostic and solutions) that can be either combined or used separately, depending on client needs and the project scope. The development of Apollo Maturity™ will enable BQG to ensure strong leadership and extend its expertise to other sectors beyond pharmaceuticals, to offer tailored solutions for its clients.

Atlas services allow companies to entrust the complete management of a project to BQG in order to resolve a specific issue or challenge. This is a long-term, results-based commitment for an inclusive price.

About the Biotech Quality Group

The Biotech Quality Group (BQG) is an advisory firm that specializes in improving the performance of biopharmaceutical and medical device companies. By anticipating the specific challenges of the evolution of stricter regulations, it enables the resolution of non-conformity issues in quality and production.

BQG stands out thanks to the disruptive tools and methodologies developed by its R&D department with the support of the Brussels Institute of Scientific Research (Innoviris). Amongst its innovations are collaborative diagnostics and solutions for anchoring Apollo Maturity™ results. These enable the industry to break free of one of its oldest paradigms: performance or compliance. Following a diagnostic stage, companies implement tailored solutions that allow them to reach their quality objectives while meeting specific deadlines within budget.

BQG was one of the four finalists for the 2016 EY Promising Company of the Year Prize in Belgium.

Created in 2011 by Fabrice Dekoninck, Yvan Gouttebelle, Philippe Billaud and Philippe Kalmbach, BQG is the result of a successful partnership between experts in value creation, quality and project management, and continuous improvement. BQG now boasts 75 expert employees across Belgium, Switzerland and France.

For more information, Please contact:

Media and Analysts Contact
Andrew Lloyd & Associates

Agnes Stephens - Lise Beltzung
agnes@ala.com - lise@ala.com
Tel: +44 1273 675100

www.thebiotechqualitygroup.com

